ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

efdoralprin alfa

A development code. Also written as “INBRX-101/rhAAT-Fc”.

Its studies are mostly in alpha 1-Antitrypsin Deficiency, led by Inhibrx Biosciences.

Furthest: phase 1, since Jan 21, 20191 company-led study, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Inhibrx Biosciences10 open or runningphase 1since Jan 21, 2019Jan 21, 2019none ahead
  • Named in sanofi’s own pipeline as efdoralprin alfa, phase 2, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 21, 2019First study: phase 1 study in alpha 1-Antitrypsin DeficiencyFirst studyNCT03815396 · 31 enrolled · United States, New Zealand, United Kingdom

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03815396alpha 1-Antitrypsin Deficiency · United States, New Zealand, United Kingdom1CompletedAug 18, 202231

How it is read

Names in the registry

  • “INBRX-101/rhAAT-Fc”, 1 entry

Codes read as this program: INBRX101.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.